menu
    • menu
    [{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Obiltoxaximab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elusys Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Obiltoxaximab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elusys Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Elusys Therapeutics \/ Heat Biologics"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Elusys Therapeutics \/ Heat Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Elusys Therapeutics

    Menu

    Elusys Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elusys Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Heat Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Heat Biologics (NightHawk Biosciences) Completes Acquisition of Elusys Therapeutics

                            Details : Pursuant to this acquisition, NightHawk announced it plans to migrate manufacturing of ANTHIM® to its planned Scorpion biomanufacturing facility in Manhattan, Kansas, which is being constructed to support development of commercial-scale biologics and la...

                            Brand Name : Anthim

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 20, 2022

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Heat Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Elusys Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Heat Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

                            Details : The strategic acquisition of Elusys is intended to enhance Heat’s immunotherapy portfolio and further position Heat to take a lead role in the biodefense space. The addition of ANTHIM (obiltoxaximab) Injection, together with Heat’s previously announc...

                            Brand Name : Anthim

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 21, 2021

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Heat Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Elusys Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Elusys Therapeutics Receives Positive CHMP Opinion For Obiltoxaximab SFL For The Treatment Of Inhalation Anthr...

                            Details : Obiltoxaximab SFL is indicated in all age groups in combination with appropriate antibacterial drugs for the treatment of inhalational anthrax due to Bacillus anthracis; and for post-exposure prophylaxis of inhalational anthrax when alternative therapies...

                            Brand Name : Obiltoxaximab SFL

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 08, 2020

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Elusys Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Elusys Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Elusys Therapeutics Receives Health Canada Approval For Anthim® For The Treatment Of Inhalation Anthrax

                            Details : Health Canada has approved the company's New Drug Submission (NDS) for Anthim (obiltoxaximab for injection), the company's monoclonal antibody (mAb) anthrax antitoxin for the treatment of inhalation anthrax.

                            Brand Name : Anthim

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 12, 2020

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth